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Treatment-resistant mood disorders pose a great socioeco-
nomic and life-threatening burden on public health system. On one 
hand, major depressive disorder (MDD) has a lifetime prevalence 
of 17-21%, and it is a leading cause of disability adjusted life years 
worldwide accordingly to The Global Burden of Disease study1. 
However, only 30-40% of patients achieve remission following a 
standard trial with a first-line antidepressant agent2. On the other 
hand, bipolar disorder (BD) affects about 2% of the world’s popula-
tion, with subthreshold forms affecting another 2%3. It is known that 
non-response in bipolar depression is also highly prevalent, and it 
occurs in 40% of patients4. Moreover, the addition of antidepressants 
to an ongoing treatment with mood stabilizers will be helpful in only 
a quarter of patients with bipolar depression5. It is also known that 
the rates of completed suicide in patients with BD are 7.8% in men 
and 4.9% in women6, which could be partially explained by treat-
ment refractoriness. Therefore, despite the pharmacological and 
psychological strategies to treat patients with mood disorders, how 
to treat the large number of patients who are refractory to them is 
still a major challenge. Lack of such knowledge is an important ques-
tion since treatment-resistant mood disorder patients are associated 
with greater morbidity, suicide attempts, as well as with extensive 
use of mood-related and general medical services7. Thus, a book on 
the subject of treatment resistance is key and of great clinical and 
public health value.
The book “Treatment-Resistant Mood Disorders”8 covers the 
forefront findings in this issue and provides a detailed outline of 
current therapeutic strategies and future therapeutic targets. It 
stands out as an essential tool for clinicians and researchers. The 
first chapters of the book looking for enlighten the reader about the 
current definitions of refractory mood disorders, as well as aspects 
related to epidemiology and assessment. Notwithstanding the lack 
of a clear consensus on a working criteria for treatment resistance 
mood disorders, several key parameters have been agreed, including 
the multi-dimensional assessment of the symptoms severity, pres-
ence of psychiatric or general medical comorbidity, and the objective 
determination of previous response to adequate treatments. One 
interesting point presented by the book is the comorbidity with 
anxiety disorders, such as posttraumatic stress disorder and panic 
disorder, which are common among treatment-resistant patients9,10. 
The likelihood of remission in anxious depression was only one third 
compared with those having pure depression for instance11. Besides 
refractoriness to antidepressants and mood stabilizers, patients with 
comorbidity anxiety disorders are also associated with functional 
impairment, poor psychosocial adjustments, more frequent hospi-
talizations, increase suicidality, and slower recovery from a mood 
episode9,10,12. 
Both chapters of predictors of treatment response in MDD and 
BD cover the substantial progress that has been made over the last 
few years in the search for clinically useful variables. In this vein, 
a recent work has led to the development of a risk stratification 
tool for treatment resistance in MDD incorporating both baseline 
socio-demographic and clinical features13. The study was innovative 
because of the use of machine learning techniques to analyze several 
variables at the same time leading to a useful predictive tool to assess 
treatment resistance. However, clinical information alone probably 
is insufficient for adequate prediction. Genetics and neurobiological 
markers may help to improve the accuracy of the clinical predictive 
tools. For instance, a large study including 1761 bipolar type-I pa-
tients from the Taiwan Bipolar Consortium showed that two single 
nucleotide polymorphism located in the introns of GADL1 gene 
(rs17026688 and rs17026651) were strongly associated with the 
response to lithium maintenance treatment14. Therefore, future stud-
ies may combine clinical, genetic, epigenetic, neuroimaging, and/or 
neurobiological markers to obtain meaningful signatures to predict 
treatment response and provide a more personalized treatment15. 
Advanced pattern recognition methods, such as machine learning 
techniques, that could integrate these characteristics may be of great 
value in this challenge.
The book also supplies updated data about evidence-based phar-
macological and psychosocial approaches for treatment-resistant 
mood disorder, as well as about the use of electroconvulsive therapy, 
which remains one of the most important tools available. The chapter 
about evidence-based pharmacological approaches for treatment-
resistant depressive disorder is one of the most important for clinical 
practice, since it provides a detailed and concise overview of the aug-
mentation and switching pharmacological strategies in MDD. Other 
strategies of non-invasive, such as transcranial magnetic stimulation 
(TMS), and invasive neurostimulation, such as deep brain stimula-
tion, are also addressed in subsequent chapters. Moreover, the last 
two chapters provide meaningful information on potential novel 
therapeutic targets for mood disorders, such as the pathophysiologi-
cal findings in the glutamatergic and immune system. In this vein, 
the fast-acting antidepressant Ketamine arises as an option in severe 
and refractory patients with MDD. Also, the better understand of 
the latter pathophysiological mechanism could shed some light on 
how to address cognitive and functional impairment associated to 
the illness progression that take place in some patients16. 
In summary, the book “Treatment-Resistant Mood Disorders” 
provides a much-needed overview of all current aspects related to 
treatment resistance in the mood disorders. It, therefore, will be of 
great value to clinicians, researchers, and public health officials in 
helping to fundamentally advance the field of psychiatric refractory 
treatment.
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